48Q0 Stock Chart & Stats
€4.90
€0.00(0.00%)
At close: 4:00 PM EDT
€4.90
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€4.90 - €5.08
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€344.92M
Enterprise Value€458.70
Total Cash (Recent Filing)€207.97M
Total Debt (Recent Filing)€77.22M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Oct 29, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding99,146,740
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)4.82
P/FCF Ratio-1.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.47Price Target Upside93.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.62
Revenue Forecast (FY)€8.39M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Gross MarginsRapid revenue growth and high gross margins indicate improving commercial traction and attractive economics on existing sales. If growth continues, these characteristics could provide operating leverage and support reinvestment as the company scales its marketed and developing therapies.
Low Leverage And Substantial Asset BaseVery low debt reduces interest and refinancing pressure, while the sizeable equity and asset base provide greater flexibility than a highly leveraged structure. This gives X4 more capacity to pursue development and commercialization milestones, although losses still require careful capital management.
Approved Product And Experienced Governance SupportAn approved therapy gives X4 a commercial foundation beyond purely pre-revenue discovery, while the new independent director adds relevant finance, capital-markets, and rare-disease expertise. Together, these assets may improve execution across commercialization, regulatory, and financing milestones.
Bears Say
Large Ongoing Operating LossesLosses remain exceptionally large relative to current revenue, showing that the cost base is far above the company’s present commercial scale. Without substantial revenue expansion or expense reduction, persistent negative margins could delay profitability and limit the durability of reported growth.
Heavy Cash Consumption And External Funding DependenceSubstantial operating and free-cash-flow deficits mean X4 is consuming capital to fund its business rather than generating cash internally. Until revenue scales or expenses decline, continued development and commercialization may depend on external financing, creating financial flexibility and execution pressure.
Potential Dilution From Expanded Equity IncentivesAn expanded equity incentive plan may help attract and retain specialized biopharma talent, but issuing additional equity can dilute existing holders over time. The trade-off is more significant while the company remains loss-making and dependent on capital to fund development.
X4 Pharmaceuticals News
48Q0 FAQ
What was X4 Pharmaceuticals Inc’s price range in the past 12 months?
X4 Pharmaceuticals Inc lowest stock price was €4.90 and its highest was €5.08 in the past 12 months.
What is X4 Pharmaceuticals Inc’s market cap?
X4 Pharmaceuticals Inc’s market cap is €344.92M.
When is X4 Pharmaceuticals Inc’s upcoming earnings report date?
X4 Pharmaceuticals Inc’s upcoming earnings report date is Oct 29, 2026 which is in 52 days.
How were X4 Pharmaceuticals Inc’s earnings last quarter?
X4 Pharmaceuticals Inc released its earnings results on Aug 06, 2026. The company reported -€0.113 earnings per share for the quarter, beating the consensus estimate of -€0.152 by €0.04.
Is X4 Pharmaceuticals Inc overvalued?
According to Wall Street analysts X4 Pharmaceuticals Inc’s price is currently Undervalued.
Does X4 Pharmaceuticals Inc pay dividends?
X4 Pharmaceuticals Inc does not currently pay dividends.
What is X4 Pharmaceuticals Inc’s EPS estimate?
X4 Pharmaceuticals Inc’s EPS estimate is -0.16.
How many shares outstanding does X4 Pharmaceuticals Inc have?
X4 Pharmaceuticals Inc has 99,146,740 shares outstanding.
What happened to X4 Pharmaceuticals Inc’s price movement after its last earnings report?
X4 Pharmaceuticals Inc reported an EPS of -€0.113 in its last earnings report, beating expectations of -€0.152. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of X4 Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in DE:48Q0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
X4 Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.47 (93.31% Upside)
€9.47 (93.31% Upside)
Blogger Sentiment
Bullish
DE:48Q0 Sentiment 60%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth €306.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
140.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
48Q0 Stock 12 Month Forecast
Average Price Target
€9.47
▲(93.31% Upside)